Literature DB >> 1280496

Granulocyte colony-stimulating factor treatment in AIDS patients.

U R Hengge1, N H Brockmeyer, M Goos.   

Abstract

Frequent complications of human immunodeficiency virus infection are hematopoietic failure and poor tolerance of myelosuppressive drugs. Reasons for neutropenia resulting from hematopoietic failure are infection of the bone marrow and hematotoxicity of treatment with zidovudine, ganciclovir, sulfonamides, and interferons. Moreover, tumor necrosis factor-alpha, transforming growth factor-beta and interferon-gamma have been shown to suppress proliferation of bone marrow cells. Both granulocyte (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) increase neutrophil counts and ameliorate phagocytic and bactericidic function of neutrophils. We report eight cases of AIDS patients with serious infections and neutropenia (< 750 cells/microliters), who were treated concomitantly with recombinant human G-CSF (3-4 micrograms subcutaneously per kilogram body weight daily). G-CSF treatment was well tolerated in all patients and showed no side effects or disturbances of other lineages than neutrophils. Life-threatening bacterial infections were treated successfully by stimulating the neutrophil immune system. This therapy shortened the duration of subsequent treatment with antibiotics. Since human immunodeficiency virus infects CD4-positive monocytes and macrophages, which are stimulated by GM-CSF, G-CSF seems to be the cytokine of choice, if stimulation of the neutrophil lineage is warranted.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280496     DOI: 10.1007/BF00180439

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  25 in total

1.  Lack of evidence for infection of or effect on growth of hematopoietic progenitor cells after in vivo or in vitro exposure to human immunodeficiency virus.

Authors:  J M Molina; D T Scadden; M Sakaguchi; B Fuller; A Woon; J E Groopman
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

2.  Effect of recombinant human granulocyte colony-stimulating factor on Pneumocystis carinii infection in nude mice.

Authors:  R Ieki; T Furuta; S Asano; S Mori; S Kudoh; H Kimura; F Takaku
Journal:  Jpn J Exp Med       Date:  1989-04

3.  Neutrophil-bound immunoglobulin in HIV infection is of autoantibody nature.

Authors:  R J Klaassen; A B Vlekke; A E von dem Borne
Journal:  Br J Haematol       Date:  1991-03       Impact factor: 6.998

4.  Absent or rare human immunodeficiency virus infection of bone marrow stem/progenitor cells in vivo.

Authors:  B R Davis; D H Schwartz; J C Marx; C E Johnson; J M Berry; J Lyding; T C Merigan; A Zander
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

5.  Stimulation and priming of human neutrophils by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: qualitative and quantitative differences.

Authors:  A Yuo; S Kitagawa; A Ohsaka; M Saito; F Takaku
Journal:  Biochem Biophys Res Commun       Date:  1990-08-31       Impact factor: 3.575

Review 6.  The use of hematopoietic growth factors in HIV infection and AIDS-related malignancies.

Authors:  S A Miles
Journal:  Cancer Invest       Date:  1991       Impact factor: 2.176

7.  Neutrophil kinetics of recombinant human granulocyte colony-stimulating factor-induced neutropenia in rats.

Authors:  Y Okada; M Kawagishi; M Kusaka
Journal:  Life Sci       Date:  1990       Impact factor: 5.037

8.  Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils.

Authors:  E Roilides; T J Walsh; P A Pizzo; M Rubin
Journal:  J Infect Dis       Date:  1991-03       Impact factor: 5.226

9.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome.

Authors:  J E Groopman; R T Mitsuyasu; M J DeLeo; D H Oette; D W Golde
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245

10.  Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.

Authors:  M H Bronchud; J H Scarffe; N Thatcher; D Crowther; L M Souza; N K Alton; N G Testa; T M Dexter
Journal:  Br J Cancer       Date:  1987-12       Impact factor: 7.640

View more
  3 in total

Review 1.  Filgrastim in patients with neutropenia: potential effects on quality of life.

Authors:  Gary H Lyman; Nicole M Kuderer
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Pharmacoeconomic evaluation of lenograstim. Conclusions and future directions.

Authors:  J Menzin; G Oster; V Cour-Chabernaud; D Richard
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

Review 3.  Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.

Authors:  J E Frampton; C R Lee; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.